文献速递糖尿病

SARS-CoV-2感染与COVID-19疫苗接种及新发1型糖尿病风险:瑞典注册人群研究

SARS-CoV-2 infection and COVID-19 vaccination and the risk for new-onset type 1 diabetes: a register-based population study in Sweden.
PubMed 文献 · Diabetologia · 2026-06-06

基于瑞典注册队列(2,650,492名儿童和6,870,328名成人),研究SARS-CoV-2感染与疫苗接种后新发1型糖尿病风险。感染后2年内儿童HR 1.22(95%CI 1.10,1.36)、成人HR 1.10(1.00,1.20),风险主要集中于感染后0-30天(儿童HR 5.41,成人HR 3.33)。疫苗接种未修饰感染相关风险,儿童接种后2年内HR 0.77,成人首剂后0-30天HR 1.32。结论支持检测/诊断加速而非持续因果效应。

要点

  • 感染后0-30天新发1型糖尿病诊断风险显著升高,儿童HR 5.41,成人HR 3.33。
  • 感染后2年内风险轻度升高,儿童HR 1.22,成人HR 1.10。
  • 疫苗接种未改变感染相关风险(交互作用P>0.5),不支持持续因果效应。

核心结论

  • 感染后及首剂疫苗接种后30天内新发1型糖尿病诊断短期升高,但未持续,支持检测/诊断加速而非持续因果效应。

研究设计与样本

  • 基于瑞典注册的队列研究,纳入2020年1月1日所有<80岁居民及随访期间出生者,随访至2023年12月31日。
  • 队列含2,650,492名儿童(3813例新发1型糖尿病)和6,870,328名成人(4453例新发1型糖尿病)。
  • 采用以日历时间为时间尺度的Cox回归,暴露为时变变量,按年龄分层(<18岁儿童;18-79岁成人)并调整年龄相应协变量。
  • 风险窗口为感染后(及每剂疫苗后)0-30天、31-180天、181-365天和1-2年。
  • 儿童敏感性分析限于12-17岁。

主要发现

  • SARS-CoV-2感染后2年内儿童新发1型糖尿病风险升高(HR 1.22;95%CI 1.10,1.36),成人亦升高(HR 1.10;95%CI 1.00,1.20)。
  • 风险主要集中于感染后0-30天窗口(儿童HR 5.41;95%CI 4.34,6.74;成人HR 3.33;95%CI 2.69,4.12)。
  • 疫苗接种未修饰感染相关风险(交互作用P>0.5)。
  • 以疫苗接种为暴露时,儿童2年内HR降低(0.77;95%CI 0.67,0.88),但12-17岁亚组未观察到(HR 1.00;95%CI 0.80,1.26)。
  • 成人首剂疫苗接种后0-30天风险轻度升高(HR 1.32;95%CI 1.07,1.62),后续窗口或剂次未见。

临床怎么用

  • 感染后30天内出现高血糖症状时应警惕新发1型糖尿病,但风险升高为短暂现象,不支持长期因果关联。
  • 疫苗接种后短期风险信号不持续,不应因此改变疫苗接种建议。

局限性

  • 注册研究设计可能受检测偏倚影响,感染后短期诊断增加可能反映检测加速。
  • 儿童疫苗接种与1型糖尿病风险降低的关联在12-17岁亚组中未重现,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Reports from several countries suggested increased incidence of type 1 diabetes during the COVID-19 pandemic, but causality has remained unclear. We investigated incident type 1 diabetes related to SARS-CoV-2 infection and vaccination in Swedish children and adults and assessed whether vaccination modified infection-related risk. METHODS: We assembled a register-based cohort of all residents aged <80 years on 1 January 2020 and births during follow-up (1 January 2020-31 December 2023). Risk windows after infection (and after each vaccine dose) were 0-30 days, 31-180 days, 181-365 days, and 1-2 years. Incident type 1 diabetes was defined by the earliest ICD-10 diagnosis E10 in the National Diabetes Register or in the National Patient Register. Cox regression with calendar time as the timescale was used with time-varying exposures; analyses were stratified by age (children <18 years; adults 18-79 years), with age-appropriate covariate adjustment. Sensitivity analyses for children were restricted to ages 12-17 years. RESULTS: The cohort included 2,650,492 children (3813 incident type 1 diabetes) and 6,870,328 adults (4453 incident type 1 diabetes). SARS-CoV-2 infection was associated with increased type 1 diabetes risk within 2 years in children (hazard ratio [HR] 1.22; 95% confidence interval 1.10, 1.36) and adults (1.10; 1.00, 1.20), driven largely by the 0-30-day window (5.41; 4.34, 6.74 in children, 3.33; 2.69, 4.12 in adults). Vaccination did not modify infection-associated risk (interaction p>0.5). When vaccination was investigated as the exposure, children showed lower HRs (0.77; 0.67, 0.88) within 2 years, but this association was not observed in ages 12-17 (1.00; 0.80, 1.26); adults showed a small excess risk within 0-30 days after dose 1 (1.32; 1.07, 1.62), but not in later windows or doses. CONCLUSIONS/INTERPRETATION: Short-term elevations in incident type 1 diabetes diagnoses were observed in the first 30 days after infection and after first vaccination, and did not persist, supporting detection/diagnostic acceleration rather than a sustained causal effect of SARS-CoV-2 infection or vaccination on type 1 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Li H, Morris L, Bygdell M, et al. SARS-CoV-2 infection and COVID-19 vaccination and the risk for new-onset type 1 diabetes: a register-based population study in Sweden. Diabetologia. 2026. PMID: 42251204. doi:10.1007/s00125-026-06767-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。